Oscar Health
OSCR
$31.40
+10.80%
Oscar Health, Inc. is a healthcare technology company that offers individual and family health insurance plans through federal and state-run ACA exchanges, leveraging a full-stack technology platform to deliver a member-centric experience. As a disruptive insurtech player, Oscar differentiates itself through its integrated technology and focus on consumer engagement, competing against traditional managed care giants. The current investor narrative centers on Oscar's rapid membership growth and improving underwriting performance, with the company achieving its first quarterly net profit in Q1 2026, fueling debate about its path to sustainable profitability and long-term margin expansion.…
OSCR
Oscar Health
$31.40
Related headlines
Investment Opinion: Should I buy OSCR Today?
Rating: Hold. Oscar Health is a high-growth insurtech that has achieved a critical profitability inflection, but the stock already prices in much of the optimism. The consensus 'Hold' rating and average target of $24.20 suggest limited upside from the current $28.19. Supporting Evidence: Revenue is accelerating at 52.6% YoY, gross margin improved to 30.5% from 10.9% a year ago, and the company generated $2.62B in free cash flow in Q1 2026. The forward P/E of 18.6x is reasonable given the growth rate, but the stock trades at a 24% premium to the sector average. The PEG ratio of 0.005 implies undervaluation, but this extreme figure may normalize as earnings stabilize. Risks & Conditions: The biggest risks are a failure to sustain profitability (Q1 2026 net income of $679M must be repeated), regulatory changes to ACA exchanges, and competitive pressure from larger insurers. This Hold would upgrade to Buy if the stock pulls back to the analyst average of $24.20 or below, providing a margin of safety, or if the company delivers another quarter of strong profitability. It would downgrade to Sell if revenue growth decelerates below 30% or if gross margins fall below 20%. Overall, Oscar is fairly valued relative to its growth prospects but overvalued relative to the analyst consensus, making it a hold for existing investors and a cautious pass for new buyers at current levels.
Sign up to view all
OSCR 12-Month Price Forecast
Oscar Health has executed a remarkable turnaround, achieving profitability and strong cash flow generation. However, the stock's 98.5% rally over the past year has pushed it above the consensus analyst target, suggesting limited near-term upside. The base case of continued growth at a more moderate pace is most likely, with the stock consolidating near current levels. The bull case requires sustained profitability acceleration, while the bear case hinges on a reversal of the recent margin improvements. Given the balanced risk/reward, a neutral stance is warranted, with a watchful eye on upcoming quarterly results to confirm the sustainability of the profitability inflection.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Oscar Health's 12-month outlook, with a consensus price target around $24.20 and implied upside of -22.9% versus the current price.
Average Target
$24.20
0 analysts
Implied Upside
-22.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$13 - $35
Analyst target range
Oscar Health is covered by 10 analysts, with a consensus recommendation of 'Hold' and an average target price of $24.20. The current price of $28.19 implies a -14.2% downside to the average target, indicating that the stock has already exceeded the consensus view. The recommendation breakdown shows a neutral stance, with no strong bullish or bearish tilt. The average target suggests analysts see limited upside from current levels, potentially reflecting concerns about valuation after the recent run-up. The target range spans from a low of $13.00 to a high of $35.00, a wide spread of $22.00 that highlights significant uncertainty about Oscar's future. The high target of $35.00 implies 24.2% upside and likely assumes continued membership growth and margin expansion, while the low target of $13.00 implies a 53.9% decline, pricing in competitive pressures or regulatory headwinds. Recent ratings actions show upgrades: Barclays moved from Equal Weight to Overweight in June 2026, and Piper Sandler upgraded from Neutral to Overweight in November 2025. However, the consensus remains cautious, with several firms maintaining Neutral or Hold ratings. The wide target spread and neutral consensus suggest that while the stock has strong momentum, analysts are waiting for more evidence of sustained profitability before turning more bullish.
Drowning in data?
Find the real signal!
Bulls vs Bears: OSCR Investment Factors
Oscar Health presents a compelling bull case centered on its accelerating revenue growth (52.6% YoY), first-ever quarterly net profit of $679M, and expanding margins (gross margin 30.5%). The company's strong free cash flow generation ($2.62B in Q1 2026) and low PEG ratio (0.005) suggest the market may be underestimating its earnings power. However, the stock already trades 14.2% above the average analyst target of $24.20, and the consensus 'Hold' rating indicates limited near-term upside. The primary tension is whether Oscar can sustain its profitability trajectory—if it does, the forward P/E of 18.6x could prove cheap; if not, the stock could correct sharply toward the $13.00 low target. Currently, the bull case has stronger evidence given the fundamental inflection, but the stock's high beta (2.34) and premium valuation relative to peers (24% above sector average P/E) warrant caution.
Bullish
- Revenue Acceleration and Profitability Turnaround: Revenue grew 52.6% YoY in Q1 2026 to $4.65B, accelerating from 28.6% growth in Q2 2025. The company achieved its first quarterly net profit of $679M, swinging from a net loss of $228M in Q2 2025, demonstrating a clear path to sustainable profitability.
- Strong Free Cash Flow Generation: Free cash flow reached $2.62B in Q1 2026, up from $0.50B in Q2 2025, with trailing twelve-month FCF of $2.80B. This provides ample liquidity to fund growth internally and reduces dependence on external capital.
- Improving Margins and Operating Leverage: Gross margin expanded to 30.5% in Q1 2026 from 10.9% a year earlier, while net margin reached 14.6%, well above the industry average for health insurers. This reflects better underwriting and operating leverage from the technology platform.
- Low PEG Ratio Suggests Undervaluation: The forward P/E of 18.6x combined with a PEG ratio of 0.005 implies the stock is deeply undervalued relative to its earnings growth rate. Even normalizing for the recent profitability swing, the PEG remains below 1.0, indicating growth is not fully priced in.
Bearish
- Stock Exceeds Consensus Target: At $28.19, the stock trades 14.2% above the average analyst target of $24.20, suggesting limited near-term upside. The consensus recommendation is 'Hold', indicating analysts see the stock as fairly valued or slightly overvalued at current levels.
- High Beta and Volatility Risk: With a beta of 2.34, Oscar is 134% more volatile than the market. The stock has a 52-week range of $10.69 to $33.10, and its max drawdown of -51.71% highlights the potential for severe corrections, especially in a risk-off environment.
- Dependence on ACA Exchange Membership: Oscar's business is heavily concentrated in ACA exchange plans, making it vulnerable to regulatory changes, subsidy adjustments, or competitive pricing pressures. Any adverse policy shift could materially impact membership growth and margins.
- Negative Trailing ROE and Prior Losses: Despite the Q1 2026 profit, trailing twelve-month ROE is -45.3%, reflecting the cumulative impact of prior losses. The company's history of unprofitability means investors must rely on sustained execution to justify the current valuation.
OSCR Technical Analysis
Oscar Health is in a powerful sustained uptrend, with the stock surging 98.5% over the past year, dramatically outperforming the S&P 500's 16.5% gain. The current price of $28.19 sits at 85% of its 52-week range ($10.69–$33.10), indicating strong momentum but also proximity to resistance near the highs. This positioning suggests the market is pricing in continued positive catalysts, though the stock is not yet overextended relative to its recent breakout. Short-term momentum remains robust but shows signs of deceleration: the stock gained 67.7% over the past three months but has pulled back 3.3% in the last month. This divergence—a 1-month decline against a strong 1-year uptrend—could signal a healthy consolidation or profit-taking after a rapid run-up, rather than a trend reversal. The relative strength versus the S&P 500 over the past month is -4.1%, confirming the recent underperformance is stock-specific. Key support lies at the 52-week low of $10.69, while resistance is at the 52-week high of $33.10. A breakout above $33.10 would signal a continuation of the uptrend and likely attract momentum buyers, while a breakdown below recent support near $25 could indicate a deeper correction. With a beta of 2.34, Oscar is 134% more volatile than the market, meaning outsized moves in both directions—critical for position sizing and risk management.
Beta
2.34
2.34x market volatility
Max Drawdown
-51.7%
Largest decline past year
52-Week Range
$11-$33
Price range past year
Annual Return
+114.0%
Cumulative gain past year
| Period | OSCR Return | S&P 500 |
|---|---|---|
| 1m | +5.4% | +1.6% |
| 3m | +75.1% | +4.1% |
| 6m | +110.3% | +6.8% |
| 1y | +114.0% | +16.3% |
| ytd | +109.8% | +8.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OSCR Fundamental Analysis
Oscar Health's revenue trajectory is accelerating sharply, with Q1 2026 revenue of $4.65 billion representing 52.6% year-over-year growth, up from 28.6% growth in Q2 2025. This acceleration is driven by strong membership expansion in ACA plans and the company's technology platform services. The multi-quarter trend shows revenue growing from $2.21 billion in Q2 2024 to $4.65 billion in Q1 2026, more than doubling in under two years, underscoring a powerful growth phase that supports the investment case for a high-growth healthcare platform. Profitability has turned a corner: Oscar reported net income of $679 million in Q1 2026, a dramatic swing from a net loss of $228 million in Q2 2025. Gross margin improved to 30.5% in Q1 2026 from 10.9% a year earlier, reflecting better underwriting and operating leverage. The company's net margin of 14.6% in Q1 2026 is well above the industry average for health insurers, signaling that Oscar's technology-driven model can deliver superior profitability when execution is strong. Oscar's balance sheet is solid, with a debt-to-equity ratio of just 0.44 and free cash flow of $2.62 billion in Q1 2026, up from $0.50 billion in Q2 2025. The company generated $2.80 billion in trailing twelve-month free cash flow, providing ample liquidity to fund growth internally. Return on equity improved to 40.8% in Q1 2026 from negative levels a year earlier, indicating that the business is now generating strong returns on invested capital. The current ratio of 1.09 suggests adequate short-term liquidity, though the negative ROE of -45.3% on a trailing basis reflects the prior losses.
Quarterly Revenue
$4.6B
2026-03
Revenue YoY Growth
+52.5%
YoY Comparison
Gross Margin
30.5%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OSCR Overvalued?
Since Oscar Health has positive net income ($679 million in Q1 2026), we lead with the P/E ratio. The trailing P/E is not meaningful due to prior losses, but the forward P/E of 18.6x is the primary metric. The forward P/E implies the market expects continued earnings growth, as the trailing P/E is negative. The PEG ratio of 0.005 suggests the stock is deeply undervalued relative to its earnings growth rate, but this extreme figure likely reflects the recent swing to profitability and may normalize. Compared to the industry, Oscar's forward P/E of 18.6x is at a premium to the healthcare plans sector average of roughly 15x, representing a 24% premium. This premium is justified by Oscar's superior revenue growth (52.6% YoY) and improving margins, as most traditional insurers are growing in the low single digits. However, the premium also reflects the higher risk associated with Oscar's smaller scale and reliance on ACA exchange membership. Historically, Oscar's valuation has compressed dramatically: the price-to-sales ratio has fallen from over 8x in 2021 to 0.32x currently, reflecting the market's prior skepticism about profitability. The current forward P/E of 18.6x is near the low end of its historical range, suggesting the market is not yet fully pricing in the earnings recovery. This could represent a value opportunity if Oscar sustains profitability, but it also implies that any earnings miss would lead to multiple contraction.
PE
-8.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~5x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-3.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Oscar's balance sheet is solid with a debt-to-equity ratio of 0.44 and strong free cash flow, but the company's history of losses (trailing ROE of -45.3%) means that the Q1 2026 profitability must be sustained. Revenue concentration in ACA exchange plans exposes the company to membership churn and pricing pressure. The current ratio of 1.09 indicates adequate liquidity, but any deterioration in underwriting margins could quickly reverse the positive earnings momentum. Market & Competitive Risks: The stock's forward P/E of 18.6x represents a 24% premium to the healthcare plans sector average of 15x, leaving it vulnerable to multiple compression if growth decelerates. With a beta of 2.34, Oscar is highly sensitive to macro shocks and sector rotation. Recent news of increased Medicare Advantage payments benefits larger competitors like UnitedHealth, potentially intensifying competition for members. The wide analyst target spread ($13-$35) reflects deep uncertainty about Oscar's competitive positioning. Worst-Case Scenario: A combination of regulatory headwinds (e.g., ACA subsidy cuts), competitive pricing pressure, and rising medical costs could cause Oscar to miss earnings estimates, triggering analyst downgrades and multiple compression. In this scenario, the stock could fall to the analyst low target of $13.00, representing a 53.9% decline from the current price of $28.19. The 52-week low of $10.69 provides a further downside reference, implying a 62.1% loss. Given the stock's high beta and history of drawdowns (max -51.71%), such a decline is plausible under adverse conditions.
FAQ
The key risks are: 1) Financial risk: Oscar's trailing ROE is -45.3%, and the Q1 2026 profitability must be sustained—any reversal could trigger a sharp selloff. 2) Regulatory risk: The company's business is concentrated in ACA exchange plans, making it vulnerable to subsidy cuts or policy changes. 3) Competitive risk: Larger insurers like UnitedHealth have greater scale and resources, and recent Medicare Advantage payment increases may strengthen their competitive position. 4) Valuation risk: The stock trades at a 24% premium to the sector average P/E and 14.2% above the analyst average target, leaving it susceptible to multiple compression. The most severe risk is a 53.9% decline to the analyst low target of $13.00 if adverse conditions materialize.
The 12-month outlook for OSCR is balanced, with a base case probability of 50% that the stock trades in a range of $24.20 to $28.19, reflecting continued growth at a more moderate pace. The bull case (25% probability) sees the stock reaching $33.10 to $40.00 if profitability accelerates and membership growth remains strong. The bear case (25% probability) targets $10.69 to $13.00 if profitability reverses or regulatory headwinds emerge. The most likely scenario is the base case, where the stock consolidates near current levels as the market digests the recent rally. Key assumptions include sustained revenue growth above 30% YoY and gross margins holding near 25-30%. Investors should monitor upcoming quarterly results for confirmation of the profitability trend.
Oscar Health's forward P/E of 18.6x is at a 24% premium to the healthcare plans sector average of 15x, suggesting it is somewhat overvalued relative to peers. However, the PEG ratio of 0.005 implies the stock is deeply undervalued relative to its earnings growth rate, though this extreme figure reflects the recent swing to profitability and may normalize. Historically, the price-to-sales ratio has compressed from over 8x in 2021 to 0.32x currently, indicating the market previously priced in significant skepticism. The current valuation implies the market expects continued earnings growth, but the stock already exceeds the consensus target, leaving little room for error. Overall, OSCR appears fairly valued to slightly overvalued based on analyst targets, but could prove cheap if the company sustains its current profitability trajectory.
Oscar Health is a high-risk, high-reward stock that may be suitable for aggressive growth investors. The company has achieved a critical profitability inflection, with Q1 2026 net income of $679M and revenue growth of 52.6% YoY. However, the stock trades at $28.19, which is 14.2% above the average analyst target of $24.20, suggesting limited near-term upside. The consensus rating is 'Hold', reflecting caution. For investors with a long-term horizon and high risk tolerance, OSCR could be a good buy on pullbacks toward the analyst average target, where the risk/reward becomes more favorable. The biggest downside risk is a 53.9% decline to the analyst low target of $13.00 if profitability reverses.
Oscar Health is better suited for long-term investment given its high volatility (beta of 2.34) and the early stage of its profitability turnaround. Short-term traders may find opportunities in the stock's wide daily swings, but the 3.3% decline over the past month suggests recent momentum is fading. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the company to compound its growth and expand margins. The stock does not pay a dividend, so returns are entirely dependent on capital appreciation. The company's strong free cash flow generation ($2.62B in Q1 2026) and improving margins provide a foundation for long-term value creation, but the high beta means investors must tolerate significant drawdowns along the way.